IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: Welner et al. demonstrated that a specific IL6-blocking antibody of protected human CD34+ cells when exposed to CML cells and that this approach might be an effective therapy in drug-resistant CML [161].